Medtronic’s New Insulin Pump Aims To Prevent Hypoglycemia
Medtronic received the go-ahead to begin an at-home U.S. trial of its Low Glucose Suspend technology that aims to prevent hypoglycemia by automatically stopping basal insulin delivery when measured glucose reaches a critically low level.
The pump technology is already available in Europe on the company’s Paradigm Veo insulin pump.
This is the second phase of the ASPIRE (Automation to Simulate Pancreatic Insulin REsponse) study, following the completion of the in-patient clinical study. ASPIRE is a multi-center, randomized, pivotal in-home study being conducted at multiple investigational centers to determine the safety and efficacy of the Low Glucose Suspend feature in the sensor-augmented MiniMed Paradigm insulin pump. Medtronic’s newest continuous glucose sensor, the Enlite™ sensor, will be tested as part of the overall system.
ASPIRE will compare Read more »
*This blog post was originally published at Medgadget*
